MRK Analyst Insights | Merck & Co., Inc.

Ratings	Buy	Hold	Sell	Other ratings	Last Close	Average Target	Upside	High Target	Low Target
(m)	(m)	(m)	(m)	(m)	$146.75	(m)	(m)	(m)	(m)

Date	Stock	Analyst	Firm	Price When Rated	Price Target	Upside / Downside	Rating
2026-07-28	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$130.76	$150.00	+14.71%	Overweight
2026-02-19	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$121.57	$140.00	+15.16%	Overweight
2024-11-29	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$103.12			Overweight
2024-10-04	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$110.18	$140.00	+27.06%	Overweight
2024-07-30	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$127.78	$142.00	+11.13%	Overweight
2024-02-01	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$126.38	$145.00	+14.73%	Overweight
2024-01-22	MRK Merck & Co., Inc.	Emily Field, CFA	Barclays	$119.43	$135.00	+13.04%	Overweight

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
AbbVie Inc. (ABBV)	United States	$468.180B	70.37
ABBOTT LABORATORIES (ABT)	United States	$176.045B	28.47
PFIZER INC (PFE)	United States	$162.042B	31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
JOHNSON & JOHNSON (JNJ)	United States	$652.528B	29.10
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60